Relevance of CYP1B1 genetic polymorphism and individual therapy

doi:10.12092/j.issn.1009-2501.2018.11.019

Abstract

Abstract:

CYP1B1 is a member of the cytochrome P450 (CYP450s) family. As a phase I metabolizing enzyme, CYP1B1 is involved in the maintenance of normal structure and physiological function in the human body through catalyzing the metabolism of hormones, fatty acids, vitamins, exogenous chemicals and drugs. It has been found that CYP1B1 gene polymorphism can affect its protein expression and enzyme activity, thus having an impact on the metabolic processes that it catalyzes, especially the changes in the metabolic processes of sex hormones and exogenous substances which are closely related to the occurrence and treatment of glaucoma, various types of cancer and other diseases. Studying on the metabolic pathways involving CYP1B1 and on the influence of its gene polymorphisms will help us understand the role of metabolic pathway changes in the development of related diseases and in the medical treatment, deepen our understanding of diseases such as cancer and glaucoma, and facilitate the detection and assessment of the risk of diseases at the genetic level, so as to achieve early detection and prevention of the diseases, to provide evidence for personalized medicine, thus improving the quality of life and prolonging the survival period. This article reviews the research progress of metabolic pathways involving CYP1B1 and the impact of genetic polymorphisms in recent five years.

Key words: CYP1B1, metabolism, genetic polymorphism, cancer, glaucoma

CLC Number:

R968
R394

CHEN Binyao, LI Ling, ZHAO Huijia, LIU Xiaohong, QI Zhenhua, SUN Gongpeng, HAO Zhuowen, FAN Zhipeng, DONG Li, YUE Jiang, YE Qifa. Relevance of CYP1B1 genetic polymorphism and individual therapy[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(11): 1309-1316.

References

［1］Li F, Zhu W, Gonzalez FJ, et al. Potential role of CYP1B1 in the development and treatment of metabolic diseases［J］. Pharmacol Ther, 2017, 178:18-30.
［2］Banerjee A, Chakraborty S, Chakraborty A, et al. Functional and Structural Analyses of CYP1B1 Variants Linked to Congenital and Adult-OnsetGlaucoma to Investigate the Molecular Basis of These Diseases［J］. PLoS One, 2016, 11(5):e0156252.
［3］Go RE, Hwang KA, Choi KC, et al. Cytochrome P450 1 family and cancers［J］. J Steroid Biochem Mol Biol, 2015,47:24-30.
［4］Xu Q, Chen J, Wei Z, et al. Sex hormone metabolism and threatened abortion［J］. Med Sci Monit, 2017, 23:5041-5048.
［5］Cavalieri E, Rogan E.The molecular etiology and prevention of estrogen-initiated cancers: Ockham's Razor: Pluralitas non est ponenda sine necessitate. Plurality should not be posited without necessity［J］. Mol Aspects Med, 2014 ,36:1-55.
［6］Callahan CL, Bonner MR, Nie J, et al. Lifetime exposure to ambient air pollution and methylation of tumor suppressor genes in breast tumors［J］. Environ Res, 2018, 161:418-424.
［7］Casto KV, Edwards DA. Testosterone, cortisol, and human competition［J］. Horm Behav, 2016,82:21-37.
［8］Casado FL. The aryl hydrocarbon receptor relays metabolic signals to promote cellular regeneration［J］. Stem Cells Int, 2016,2016:4389802.
［9］Hsu MH, Baer BR, Rettie AE, et al. The crystal structure of cytochrome P450 4B1 (CYP4B1) monooxygenase complexed with octane discloses several structural adaptations for ω-hydroxylation［J］. J Biol Chem, 2017, 292(13):5610-5621.
［10］Zanger UM, Schwab M. Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation［J］. Pharmacol Ther, 2013,138(1):103-141.
［11］Chawla B, Swain W, Williams AL, et al. Retinoic acid maintains function of neural crest-derived ocular and craniofacial structures in adult zebrafish［J］. Invest Ophthalmol Vis Sci, 2018,59(5):1924-1935.
［12］Larsen MC, Bushkofsky JR, Gorman T, et al. Cytochrome P450 1B1: An unexpected modulator of liver fatty acid homeostasis［J］. Arch Biochem Biophys, 2015,571:21-39.
［13］Li F, Zhu W, Gonzalez FJ. Potential role of CYP1B1 in the development and treatment of metabolic diseases［J］. Pharmacol Ther, 2017,178:18-30.
［14］Williams AL, Eason J, Chawla B, et al. Cyp1b1 regulates ocular fissure closure through a retinoic acid-independent pathway［J］. Invest Ophthalmol Vis Sci, 2017,58(2):1084-1097.
［15］Mookherjee S, Acharya M, Banerjee D, et al. Molecular basis for involvement of CYP1B1 in MYOC upregulation and its potential implication inglaucoma pathogenesis［J］. PLoS One, 2012,7(9):e45077.
［16］Zhao Y, Wang S, Sorenson CM, et al. Cyp1b1 mediates periostin regulation of trabecular meshwork development by suppression ofoxidative stress［J］. Mol Cell Biol,2013,33(21):4225-4240.
［17］Lewis CJ, Hedberg-Buenz A, DeLuca AP, et al. Primary congenital and developmental glaucomas［J］. Hum Mol Genet, 2017,26(R1):R28-R36.
［18］Wang L, Li Z, Jin L, et al. Indoor air pollution and neural tube defects: effect modification by maternal genes［J］. Epidemiology, 2014,25(5):658-665.
［19］Bolton JL, Dunlap T. Formation and biological targets of quinones: cytotoxic versus cytoprotective effects［J］. Chem Res Toxicol, 2017,30(1):13-37.
［20］He Y, Chevillet JR, Liu G, et al. The effects of microRNA on the absorption, distribution, metabolism and excretion of drugs［J］. Br J Pharmacol, 2015,172(11):2733-2747.
［21］Zahid M, Beseler CL, Hall JB, et al. Unbalanced estrogen metabolism in ovarian cancer［J］. Int J Cancer, 2014, 134(10):2414-2423.
［22］Jiang W, Sun G, Xiong J, et al. Association of CYP1B1 L432V polymorphism with urinary cancer susceptibility: a meta-analysis［J］. Diagn Pathol, 2014, 9:113.
［23］Duran R, Cravo-Laureau C. Role of environmental factors and microorganisms in determining the fate of polycyclic aromatic hydrocarbons in the marine environment［J］. FEMS Microbiol Rev, 2016, 40(6):814-830.
［24］Hardonnière K, Saunier E. The environmental carcinogen benzo［a］pyrene induces a Warburg-like metabolic reprogramming dependent on NHE1 and associated with cell survival［J］. Sci Rep, 2016,6:30776.
［25］Baugh EH, Ke H. Why are there hotspot mutations in the TP53 gene in human cancers［J］? Cell Death Differ, 2018, 25(1):154-160.
［26］Vineis P, Veglia F, Garte S, et al. Genetic susceptibility according to three metabolic pathways in cancers of the lung and bladderand in myeloid leukemias in nonsmokers［J］. Ann Onco, 2007,18(7):1230-1242.
［27］Schults MA, Chiu RK, Nagle PW, et al. Genetic polymorphisms in catalase and CYP1B1 determine DNA adduct formation bybenzo(a)pyrene ex vivo［J］. Mutagenesis, 2013,28(2):181-185.
［28］Gu CY, Li GX, Zhu Y, et al. A single nucleotide polymorphism in CYP1B1 leads to differential prostate cancer risk andtelomere length［J］. J Cancer, 2018, 9(2):269-274.
［29］Liu C, Cui H, Gu D, et al. Genetic polymorphisms and lung cancer risk: Evidence from meta-analyses and genome-wide association studies［J］. Lung Cancer, 2017, 113:18-29.
［30］Price DK, Chau CH, Till C, et al. Association of androgen metabolism gene polymorphisms with prostate cancer risk andandrogen concentrations: Results from the Prostate Cancer Prevention Trial［J］. Cancer, 2016,122(15):2332-2340.
［31］Haddad SA, Lunetta KL, Ruiz-Narváez EA, et al. Hormone-related pathways and risk of breast cancer subtypes in African American women［J］. Breast Cancer Res Treat, 2015, 154(1):145-154.
［32］Lopes BA, Emerenciano M, Goncalves BA, et al. Polymorphisms in CYP1B1, CYP3A5, GSTT1, and SULT1A1 are associated with early age acuteleukemia［J］. PLoS One, 2015,10(5):e0127308.
［33］Jin J, Lin F, Liao S, et al. Effects of SNPs (CYP1B1*2 G355T, CYP1B1*3 C4326G, and CYP2E1*5 G-1293C), smoking, anddrinking on susceptibility to laryngeal cancer among Han Chinese［J］. PLoS One, 2014,9(10):e106580.
［34］Li C, Long B, Qin X, et al. Cytochrome P1B1 (CYP1B1) polymorphisms and cancer risk: a meta-analysis of 52 studies［J］. Toxicology, 2015,327:77-86.
［35］Maurya SS, Katiyar T, Dhawan A, et al. Gene-environment interactions in determining differences in genetic susceptibility to cancer in subsites of the head and neck［J］. Environ Mol Mutagen, 2015,56(3):313-321.
［36］Teng Y, He C, Zuo X, et al. Catechol-O-methyltransferase and cytochrome P-450 1B1 polymorphisms and endometrial cancer risk: a meta-analysis［J］. Int J Gynecol Cancer, 2013,23(3):422-430.
［37］Christensen CH, Barry KH, Andreotti G, et al. Sex steroid hormone single-nucleotide polymorphisms, pesticide use, and the risk of prostate cancer: a nested case-control study within the agricultural health study［J］. Front Oncol, 2016,6:237.
［38］Li Y, Tan SQ, Ma QH, et al. CYP1B1 C4326G polymorphism and susceptibility to cervical cancer in Chinese Han women［J］. Tumour Biol, 2013,34(6):3561-3567.
［39］Do T, Shei W, Chau PT, et al. CYP1B1 and MYOC Mutations in Vietnamese Primary Congenital Glaucoma Patients［J］. J Glaucoma, 2016,25(5):e491-498.
［40］Gong B, Qu C, Li X, et al. Mutation spectrum of CYP1B1 in Chinese patients with primary open-angle glaucoma［J］. Br J Ophthalmol, 2015,99(3):425-430.
［41］Wang L, Li Z, Jin L, et al. Indoor air pollution and neural tube defects: effect modification by maternal genes［J］. Epidemiology, 2014,25(5):658-665.
［42］Miki Y, Hata S, Ono K, et al. Roles of aryl hydrocarbon receptor in aromatase-dependent cell proliferation in human osteoblasts［J］. Int J Mol Sci, 2017,18(10):2159.
［43］Li C, Wang Z, Wang Q, et al. Enhanced anti-tumor efficacy and mechanisms associated with docetaxel-piperine combination- in vitro and in vivo investigation using a taxane-resistant prostate cancer model［J］. Oncotarget, 2017,9(3):3338-3352.
［44］Laroche-Clary A, Le Morvan V, Yamori T, et al. Cytochrome P450 1B1 gene polymorphisms as predictors of anticancer drug activity: studieswith in vitro models［J］. Mol Cancer Ther, 2010, 9(12):3315-3321.
［45］Cavaco I, Piedade R, Msellem MI, et al. Cytochrome 1A1 and 1B1 gene diversity in the Zanzibar islands［J］. Trop Med Int Health, 2012, 17(7):854-857.
［46］Stewart DA, Winnike JH, McRitchie SL, et al. Metabolomics analysis of hormone-responsive and triple-negative breast cancer cell responses to paclitaxel identify key metabolic differences［J］. J Proteome Res, 2016,15(9):3225-3240.
［47］Reinhart JM, Motsinger-Reif A, Dickey A, et al. Genome-wide association study in immunocompetent patients with delayed hypersensitivity to sulfonamide antimicrobials［J］. PLoS One, 2016,11(6):e0156000.

[1]	YOU Rongli, HUANG Yurong, MAORui, HAI Lina, WANG Yingli, WANG Yan. Mechanism of compound kushen injection in the treatment of lung cancer based on serum metabolomics and network pharmacology [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(9): 988-999.
[2]	MA Yan, TIAN Gaopeng, SHI Xingwen, SUN Ting, XIE Jingjing, ZHEN Donghu. Correlation between 25(OH)D and metabolically related fatty liver in T2DM population [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(9): 1018-1026.
[3]	HE Lihua, ZHU Xiuzhi, JIANG Yizhou. Research progress on immunotherapy for triple-negative breast cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(8): 842-853.
[4]	ZHANG Huyunlong, ZHU Xiuzhi, JIN Xi, SHAO Zhimin. Mechanisms of endocrine-resistance and therapeutic breakthroughs in hormone receptor-positive, HER2-negative breast cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(8): 854-865.
[5]	FU Xiaoyu, KONG Deguang, LI Juanjuan. Treatment progress of triple positive breast cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(8): 866-875.
[6]	LUO Shiping, ZHANG Jie, YU Yushuai, SONG Chuangui. Advances in targeted therapy for HER2-positive breast cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(8): 876-886.
[7]	XIANG Yimei, ZHANG Ningning, HUANG Yuxin, ZENG Xiaohua. Research progress of biomarkers related to the efficacy of HER2 positive breast cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(8): 887-897.
[8]	CHEN Keyu, HUANG Yuan, WANG Xiaojia, ZHENG Yabing. Clinical application and research progress of antibody drugs conjugation in breast cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(8): 898-909.
[9]	LI Mengxi, ZHANG Kejing, XIA Fan. Research progress in vaccine for breast cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(8): 918-925.
[10]	HOU Qiong, LIU Fei, CHEN Chuanrong. Immunotherapy combined with anti-angiogenic drugs and chemotherapy in negative driver gene and advanced non-small cell lung cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(7): 775-779.
[11]	ZHANG Jinghui, WEI Haoliang, WANG Li, LI Jingkai, ZHANG Baolai, YANG Xiaolai. Effects of AMI-1 on the activity of pancreatic cancer cells in vitro by down-regulating PRMT5 expression [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(6): 601-608.
[12]	FU Ting, LI Fang, PAN Dayan, XIA Yuanyuan, ZHANG Qiuyuan. miR-718 from exosomes of lung cancer cells induces angiogenesis by targeting PTEN [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(6): 624-632.
[13]	WANG Yan, ZHANG Jinhui, ZHAO Yongchen, LIU Hongxiang, LIU Yawei, MIAO Huanhuan, YANG Xincai. Sequoiaflavone inhibits stem cell properties such as proliferation and invasion of gastric cancer cells by down-regulating PI3K/AKT signaling pathway [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(5): 508-513.
[14]	FENG Zhuangzhuang, SONG Ruiping, DOU Pengcheng, CHEN Xinyi, ZUO Jiaojiao, SHU Jin. Effect of Zhiwei Fuwei Pills on autophagy in gastric antrum tissue of rats with precancerous lesions of gastric cancer based on mTOR/Beclin1/LC3 signaling axis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(4): 361-370.
[15]	SHI Dawei, ZHENG Xiaoyong, JIN Xiaodan, ZHAO Xiaoman, CHEN Jie, DU Xingjun. Implication of XPC rs2228001 polymorphism on the prognosis of patients with colorectal cancer who were treated with capecitabine-based adjuvant chemotherapy [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(4): 391-399.